Janux Debt To Equity from 2010 to 2024

JANX Stock  USD 46.39  1.61  3.35%   
Janux Therapeutics Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.07127072
Current Value
0.0748
Quarterly Volatility
0.26864254
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Janux Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Janux Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 13.1 M, Depreciation And Amortization of 2.1 M or Interest Expense of 4.9 M, as well as many indicators such as Price To Sales Ratio of 55.51, Dividend Yield of 0.0 or PTB Ratio of 1.44. Janux financial statements analysis is a perfect complement when working with Janux Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Janux Therapeutics Correlation against competitors.
For more information on how to buy Janux Stock please use our How to Invest in Janux Therapeutics guide.

Latest Janux Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Janux Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Janux Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Janux Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.07 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Janux Debt To Equity Regression Statistics

Arithmetic Mean(0.32)
Geometric Mean0.14
Coefficient Of Variation(83.79)
Mean Deviation0.24
Median(0.50)
Standard Deviation0.27
Sample Variance0.07
Range0.5824
R-Value0.83
Mean Square Error0.02
R-Squared0.69
Significance0.0001
Slope0.05
Total Sum of Squares1.01

Janux Debt To Equity History

2024 0.0748
2023 0.0713
2022 0.0789
2020 5.3E-4

About Janux Therapeutics Financial Statements

Janux Therapeutics investors use historical fundamental indicators, such as Janux Therapeutics' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Janux Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 0.07  0.07 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Janux Stock Analysis

When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.